A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

Abstract

A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m(2)/day or 150 mg/m(2)/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m(2)/day or 125 mg/m(2)/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity.

References 23

1. 1.

   Aaronson N. K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N. J., Filiberti A., Flechtner H., Fleishman S. B., de Haes J. C. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376.

   Not in our library10.1093/jnci/85.5.365

2. 2.

   Bleehen N. M., Newlands E. S., Lee S. M., Thatcher N., Selby P., Calvert A. H., Rustin G. J., Brampton M., Stevens M. F. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995;13(4):910-913.

   Not in our library10.1200/jco.1995.13.4.910

3. 3.

   Bower M., Newlands E. S., Bleehen N. M., Brada M., Begent R. J., Calvert H., Colquhoun I., Lewis P., Brampton M. H. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 1997;40(6):484-488.

   Not in our library10.1007/s002800050691

4. 4.

   Burger P. C., Vogel F. S., Green S. B., Strike T. A. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer. 1985;56(5):1106-1111.

   Not in our library10.1002/1097-0142(19850901)56:5<1106::aid-cncr2820560525>3.0.co;2-2

5. 5.

   Chamberlain M. C., Kormanik P. A. Practical guidelines for the treatment of malignant gliomas. West J Med. 1998;168(2):114-120.

   Not in our library

6. 6.

   Feun L. G., Savaraj N., Landy H. J. Drug resistance in brain tumors. J Neurooncol. 1994;20(2):165-176.

   Not in our library10.1007/bf01052726

7. 7.

   Fine H. A., Dear K. B., Loeffler J. S., Black P. M., Canellos G. P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71(8):2585-2597.

   Not in our library10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s

8. 8.

   Forsyth P. A., Cairncross J. G. Chemotherapy for malignant gliomas. Baillieres Clin Neurol. 1996;5(2):371-393.

   Not in our library

9. 9.

   Jaeschke R., Singer J., Guyatt G. H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407-415.

   Not in our library10.1016/0197-2456(89)90005-6

10. 10.

    Juniper E. F., Guyatt G. H., Willan A., Griffith L. E. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47(1):81-87.

    Not in our library10.1016/0895-4356(94)90036-1

11. 11.

    King M. T. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res. 1996;5(6):555-567.

    Not in our library10.1007/bf00439229

12. 12.

    McComb R. D., Burger P. C. Pathologic analysis of primary brain tumors. Neurol Clin. 1985;3(4):711-728.

    Not in our library

13. 13.
    Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) · 1992

    No notice
14. 14.

    Newlands E. S., O'Reilly S. M., Glaser M. G., Bower M., Evans H., Brock C., Brampton M. H., Colquhoun I., Lewis P., Rice-Edwards J. M. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 1996;32A(13):2236-2241.

    Not in our library10.1016/s0959-8049(96)00258-4

15. 15.

    Newton H. B., Junck L., Bromberg J., Page M. A., Greenberg H. S. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology. 1990;40(11):1743-1746.

    Not in our library10.1212/wnl.40.11.1743

16. 16.

    O'Reilly S. M., Newlands E. S., Glaser M. G., Brampton M., Rice-Edwards J. M., Illingworth R. D., Richards P. G., Kennard C., Colquhoun I. R., Lewis P. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 1993;29A(7):940-942.

    Not in our library10.1016/s0959-8049(05)80198-4

17. 17.

    Osoba D., Aaronson N. K., Muller M., Sneeuw K., Hsu M. A., Yung W. K., Brada M., Newlands E. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996;5(1):139-150.

    Not in our library10.1007/bf00435979

18. 18.

    Osoba D., Aaronson N., Zee B., Sprangers M., te Velde A. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res. 1997;6(2):103-108.

    Not in our library10.1023/a:1026429831234

19. 19.

    Osoba D., Rodrigues G., Myles J., Zee B., Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139-144.

    Not in our library10.1200/jco.1998.16.1.139

20. 20.

    Rodriguez L. A., Prados M., Silver P., Levin V. A. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer. 1989;64(12):2420-2423.

    Not in our library10.1002/1097-0142(19891215)64:12<2420::aid-cncr2820641204>3.0.co;2-b

21. 21.

    Stevens M. F., Hickman J. A., Langdon S. P., Chubb D., Vickers L., Stone R., Baig G., Goddard C., Gibson N. W., Slack J. A. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47(22):5846-5852.

    Not in our library

22. 22.

    Tsang L. L., Farmer P. B., Gescher A., Slack J. A. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol. 1990;26(6):429-436.

    Not in our library10.1007/bf02994094

23. 23.

    Vasantha Kumar A. R., Renaudin J., Wilson C. B., Boldrey E. B., Enot K. J., Levin V. A. Procarbazine hydrochloride in the treatment of brain tumors. Phase 2 study. J Neurosurg. 1974;40(3):365-371.

    Not in our library10.3171/jns.1974.40.3.0365

Cited by papers we hold 9

• Advances in Glioblastoma Therapy: An Update on Current Approaches · 2023
  No notice
• Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021 · 2022
  No notice
• Recurrent glioma clinical trial, CheckMate-143: the game is not over yet · 2017
  No notice
• Cytotoxic Autophagy in Cancer Therapy · 2014
  No notice
• Chemoresistance of glioblastoma cancer stem cells - much more complex than expected · 2011
  No notice
• Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme · 2009
  No notice
• Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study · 2009
  No notice
• Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) · 2006
  No notice
• Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids · 2003
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.